Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Karo Bio receives approval to initiate eprotirome phase III study in HeFH

Karo Bio receives approval to initiate eprotirome phase III study in HeFH

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

New research highlights urgent need to develop specific guidelines for HIV-infected children

New research highlights urgent need to develop specific guidelines for HIV-infected children

Alnylam second quarter revenue decreases to $20.6 million

Alnylam second quarter revenue decreases to $20.6 million

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

B. Braun adds Plasmat Futura System to H.E.L.P. LDL Apheresis therapy

B. Braun adds Plasmat Futura System to H.E.L.P. LDL Apheresis therapy

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Genomic study identifies MCU that regulates calcium transport into mitochondria

Genomic study identifies MCU that regulates calcium transport into mitochondria

HRT use linked to decreased risk of peripheral arterial disease in postmenopausal women

HRT use linked to decreased risk of peripheral arterial disease in postmenopausal women

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Study explores link between specific temperament traits and clinical events after heart attack

Study explores link between specific temperament traits and clinical events after heart attack

Synergy expands GC-C agonist technology to lower cholesterol

Synergy expands GC-C agonist technology to lower cholesterol

Alkem, Karo Bio partner to license eprotirome

Alkem, Karo Bio partner to license eprotirome

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam defends against Tekmira complaint, files answer and counterclaim

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.